S&P 500   4,580.26 (+0.63%)
DOW   35,678.11 (+0.53%)
QQQ   381.79 (+0.47%)
AAPL   150.80 (+1.31%)
MSFT   321.82 (-0.42%)
FB   310.14 (-0.67%)
GOOGL   2,924.52 (+0.01%)
TSLA   1,069.99 (+3.10%)
AMZN   3,390.75 (-0.05%)
NVDA   246.95 (+1.00%)
BABA   167.67 (-0.92%)
NIO   39.80 (+1.25%)
CGC   12.85 (+0.55%)
GE   103.42 (-0.41%)
AMD   121.30 (-0.80%)
MU   69.46 (+1.79%)
T   25.43 (+1.48%)
F   17.28 (+11.41%)
ACB   6.91 (+1.02%)
DIS   169.70 (+0.09%)
PFE   43.46 (+1.14%)
BA   205.50 (-0.54%)
AMC   35.25 (+1.41%)
S&P 500   4,580.26 (+0.63%)
DOW   35,678.11 (+0.53%)
QQQ   381.79 (+0.47%)
AAPL   150.80 (+1.31%)
MSFT   321.82 (-0.42%)
FB   310.14 (-0.67%)
GOOGL   2,924.52 (+0.01%)
TSLA   1,069.99 (+3.10%)
AMZN   3,390.75 (-0.05%)
NVDA   246.95 (+1.00%)
BABA   167.67 (-0.92%)
NIO   39.80 (+1.25%)
CGC   12.85 (+0.55%)
GE   103.42 (-0.41%)
AMD   121.30 (-0.80%)
MU   69.46 (+1.79%)
T   25.43 (+1.48%)
F   17.28 (+11.41%)
ACB   6.91 (+1.02%)
DIS   169.70 (+0.09%)
PFE   43.46 (+1.14%)
BA   205.50 (-0.54%)
AMC   35.25 (+1.41%)
S&P 500   4,580.26 (+0.63%)
DOW   35,678.11 (+0.53%)
QQQ   381.79 (+0.47%)
AAPL   150.80 (+1.31%)
MSFT   321.82 (-0.42%)
FB   310.14 (-0.67%)
GOOGL   2,924.52 (+0.01%)
TSLA   1,069.99 (+3.10%)
AMZN   3,390.75 (-0.05%)
NVDA   246.95 (+1.00%)
BABA   167.67 (-0.92%)
NIO   39.80 (+1.25%)
CGC   12.85 (+0.55%)
GE   103.42 (-0.41%)
AMD   121.30 (-0.80%)
MU   69.46 (+1.79%)
T   25.43 (+1.48%)
F   17.28 (+11.41%)
ACB   6.91 (+1.02%)
DIS   169.70 (+0.09%)
PFE   43.46 (+1.14%)
BA   205.50 (-0.54%)
AMC   35.25 (+1.41%)
S&P 500   4,580.26 (+0.63%)
DOW   35,678.11 (+0.53%)
QQQ   381.79 (+0.47%)
AAPL   150.80 (+1.31%)
MSFT   321.82 (-0.42%)
FB   310.14 (-0.67%)
GOOGL   2,924.52 (+0.01%)
TSLA   1,069.99 (+3.10%)
AMZN   3,390.75 (-0.05%)
NVDA   246.95 (+1.00%)
BABA   167.67 (-0.92%)
NIO   39.80 (+1.25%)
CGC   12.85 (+0.55%)
GE   103.42 (-0.41%)
AMD   121.30 (-0.80%)
MU   69.46 (+1.79%)
T   25.43 (+1.48%)
F   17.28 (+11.41%)
ACB   6.91 (+1.02%)
DIS   169.70 (+0.09%)
PFE   43.46 (+1.14%)
BA   205.50 (-0.54%)
AMC   35.25 (+1.41%)
NASDAQ:HOWL

Werewolf Therapeutics Stock Forecast, Price & News

$15.46
+0.09 (+0.59 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.21
$15.81
50-Day Range
$13.89
$18.83
52-Week Range
$11.23
$23.99
Volume
6,451 shs
Average Volume
78,896 shs
Market Capitalization
$426.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive HOWL News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Werewolf Therapeutics

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HOWL
Employees
28
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$426.20 million
Next Earnings Date
11/11/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.09 out of 5 stars

Medical Sector

485th out of 1,372 stocks

Pharmaceutical Preparations Industry

225th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Werewolf Therapeutics (NASDAQ:HOWL) Frequently Asked Questions

Is Werewolf Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Werewolf Therapeutics stock.
View analyst ratings for Werewolf Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Werewolf Therapeutics?

Wall Street analysts have given Werewolf Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Werewolf Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Werewolf Therapeutics' next earnings date?

Werewolf Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Werewolf Therapeutics
.

How were Werewolf Therapeutics' earnings last quarter?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) issued its quarterly earnings data on Thursday, August, 12th. The company reported ($3.82) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $3.45.
View Werewolf Therapeutics' earnings history
.

What price target have analysts set for HOWL?

5 analysts have issued 12-month price objectives for Werewolf Therapeutics' shares. Their forecasts range from $22.00 to $32.00. On average, they anticipate Werewolf Therapeutics' stock price to reach $26.40 in the next twelve months. This suggests a possible upside of 70.8% from the stock's current price.
View analysts' price targets for Werewolf Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Werewolf Therapeutics' key executives?

Werewolf Therapeutics' management team includes the following people:
  • Dr. Daniel J. Hicklin, Founder, CEO, Pres, Sec. & Director (Age 57)
  • Mr. Timothy W. Trost, CFO & Treasurer (Age 63)
  • Dr. Reid Leonard Ph.D., Chief Operating Officer (Age 62)
  • Dr. William Winston Ph.D., VP of Research
  • Dr. Chulani Karunatilake Ph.D., Chief Technology Officer
  • Dr. Cynthia Seidel-Dugan Ph.D., Chief Scientific Officer (Age 62)
  • Dr. Randi Isaacs M.D., Chief Medical Officer (Age 65)
  • Ms. Ellen A. Lubman M.B.A., Chief Bus. Officer (Age 45)

When did Werewolf Therapeutics IPO?

(HOWL) raised $101 million in an IPO on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Werewolf Therapeutics' stock symbol?

Werewolf Therapeutics trades on the NASDAQ under the ticker symbol "HOWL."

When did Werewolf Therapeutics' lock-up period expire?

Werewolf Therapeutics' lock-up period expired on Wednesday, October 27th. Werewolf Therapeutics had issued 7,500,000 shares in its IPO on April 30th. The total size of the offering was $120,000,000 based on an initial share price of $16.00. Since the end of Werewolf Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

How do I buy shares of Werewolf Therapeutics?

Shares of HOWL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Werewolf Therapeutics' stock price today?

One share of HOWL stock can currently be purchased for approximately $15.46.

How much money does Werewolf Therapeutics make?

Werewolf Therapeutics has a market capitalization of $426.20 million.

How many employees does Werewolf Therapeutics have?

Werewolf Therapeutics employs 28 workers across the globe.

What is Werewolf Therapeutics' official website?

The official website for Werewolf Therapeutics is werewolftx.com.

Where are Werewolf Therapeutics' headquarters?

Werewolf Therapeutics is headquartered at 1030 MASSACHUSETTS AVENUE SUITE 210, CAMBRIDGE MA, 02138.

How can I contact Werewolf Therapeutics?

Werewolf Therapeutics' mailing address is 1030 MASSACHUSETTS AVENUE SUITE 210, CAMBRIDGE MA, 02138. The company can be reached via phone at 617-952-0555 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.